Priority Review Designation for MK-3475 BLA for Proposed Indication of Unresectable or Metastatic Melanoma in Patients Who Have Been Previously Treated with IpilimumabAdvancing New Phase 3 Studies with MK-3475 in Adjuvant Melanoma, Previously-Untreated Non-Small Cell Lung Cancer, Advanced Head & Neck and Bladder CancersData from Studies in Three Different Cancer Types to be presented at 2014 ASCO Annual MeetingInitiating Phase 1 Study with Investigational Anti-GITR Antibody (MK-4166)
MRV Research
Dabrafenib improved quality of life in patients with metastatic melanoma
Patients with metastatic melanoma treated with dabrafenib demonstrated improved quality of life compared with those who received dacarbazine, according to phase 3 study results.
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma
Peregrine Pharmaceuticals, Inc. today announced the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy(R)), for the treatment of advanced melanoma. Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine (PS), a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells.
T-VEC superior to GM-CSF for unresected, metastatic melanoma
Secondary endpoint results from a multicenter, randomized phase 3 trial showed talimogene laherparepvec conferred greater benefit than granulocyte-macrophage colony-stimulating factor for patients with unresected stage IIIB/IIIC or stage IV melanoma, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting in New York.